Abstract
Previous evidence supports a role for growth hormone (GH)–insulin-like growth factor (IGF)-I deficiency in the pathophysiology of osteopenia/osteoporosis in adult thalassemia. Moreover, serum IGF-II has never been studied in this clinical condition. Thus, we elected to study the GH secretory status and the levels of circulating somatomedins, correlating these parameters with bone mineral density (BMD) and biochemical markers of bone turnover. A hundred and thirty-nine normal weight adult thalassemic patients (72 men and 67 women) were studied. Lumbar and femoral neck BMD were measured in 106/139 patients. Sixty-eight patients underwent growth hormone releasing hormone plus arginine testing. Measurement of baseline IGF-I and IGF-II was performed in all patients, while osteocalcin, C-terminal telopeptide of type I collagen (CTx), and urinary cross-linked N-telopeptides of type I collagen (NTx) were assayed in 95 of them. Femoral and lumbar osteoporosis/Z score below the expected range for age were documented in 61.3 and in 56.6 % of patients, respectively. Severe GH deficiency (GHD) was demonstrated in 27.9 % of cases, whereas IGF-I SDS was low in 86.3 %. No thalassemic patients displayed circulating levels of IGF-II below the reference range. GH peaks were positively correlated with femoral, but not lumbar, Z score. No correlations were found between GH peaks and osteocalcin, CTx and NTx. GH peaks were positively correlated with IGF-I values, which in their turn displayed a positive correlation with osteocalcin, CTx, and NTx. No correlations emerged between IGF-I values and either femoral or lumbar Z scores. No correlations were found between IGF-II and any of the following parameters: GH peaks, osteocalcin, CTx, NTx, femoral Z score, and lumbar Z score. Our study, besides providing for the first time evidence of a normal IGF-II production in thalassemia, contributes to a better understanding of the involvement of the somatotropin-somatomedin axis in the pathophysiology of bone demineralization in this disease. In particular, the contribution of GHD to femoral osteoporosis appears to be likely mediated by locally produced rather than circulating IGF-I.
Similar content being viewed by others
References
M. Scacchi, L. Danesi, A. Cattaneo, E. Valassi, F. Pecori Giraldi, C. Argento, E. D’Angelo, N. Mirra, V. Carnelli, L. Zanaboni, B. Tampieri, M.D. Cappellini, F. Cavagnini, Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites. Clin. Endocrinol. (Oxf.) 69, 202–207 (2008)
S. Perrotta, M.D. Cappellini, F. Bertoldo, V. Servedio, G. Iolascon, L. D’Agruma, P. Gasparini, M.C. Siciliani, A. Iolascon, Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br. J. Haematol. 111, 461–466 (2000)
D. Tiosano, Z. Hochberg, Endocrine complications of thalassemia. J. Endocrinol. Investig. 24, 716–723 (2001)
E. Voskaridou, E. Terpos, New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br. J. Haematol. 127, 127–139 (2004)
L. Pratelli, E. Verri, M. Fortini, S. Marconi, C. Zolezzi, P.M. Fornasari, M.R. Gamberini, V. De Sanctis, Chelation therapy and bone metabolism markers in thalassemia major. J. Pediatr. Endocrinol. Metab. 19, 1335–1342 (2006)
E. Canalis, Insulin like growth factors and the local regulation of bone formation. Bone 14, 273–276 (1993)
S. Sittadjody, R. Ilangovan, T. Thangasamy, R.C. Vignesh, S. Veni, A.G. Bertoni, S. Srinivasan, C. Subramanian, N. Srinivasan, Age-related changes in serum levels of insulin-like growth factor-II and its binding proteins correlate with calcaneal bone mineral density among post-menopausal South-Indian women. Clin. Chim. Acta 414, 281–288 (2012)
G. Brabant, A. von zur Muhlen, C. Wuster, M.B. Ranke, J. Kratzsch, W. Kiess, J.M. Ketelslegers, L. Wilhelmsen, L. Hulthén, B. Saller, A. Mattsson, J. Wilde, R. Schemer, P. Kann, Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm. Res. 60, 53–60 (2003)
P. Garnero, O. Borel, P.D. Delmas, Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin. Chem. 47, 694–702 (2001)
E. Ghigo, G. Aimaretti, L. Gianotti, J. Bellone, E. Arvat, F. Camanni, New approach to the diagnosis of growth hormone deficiency in adults. Eur. J. Endocrinol. 134, 352–356 (1996)
M. Scacchi, L. Danesi, A. Cattaneo, E. Valassi, F. Pecori Giraldi, C. Argento, E. D’Angelo, N. Mirra, V. Carnelli, L. Zanaboni, M.D. Cappellini, F. Cavagnini, Growth hormone deficiency (GHD) in adult thalassaemic patients. Clin. Endocrinol. (Oxf.) 67, 790–795 (2007)
V. De Sanctis, N. Skordis, M.C. Galati, G. Raiola, M. Giovannini, G. Candini, K. Kaffe, I. Savvides, S. Christou, Growth hormone and adrenal response to intramuscular glucagon test and its relationship to IGF-1 production and left ventricular ejection fraction in adult B-thalassemia major patients. Pediatr. Endocrinol. Rev. 8(Suppl 2), 290–294 (2011)
A.I. Pincelli, N. Masera, L. Tavecchia, M. Perotti, S. Perra, R. Mariani, A. Piperno, G. Mancia, G. Grassi, G. Masera, GH deficiency in adult B-thalassemia major patients and its relationship with IGF-1 production. Pediatr. Endocrinol. Rev. 8(2), 284–289 (2011)
D. Bansal, S. Venkateshwaran, N. Khandelwal, R.K. Marwaha, Quantitative computed tomography is unreliable for measurement of bone mineral density in inadequately chelated adolescent patients with beta-thalassemia major: a case-control study. Pediatr. Blood Cancer 56, 409–412 (2011)
L.S. Topor, P. Melvin, C. Giancaterino, C.M. Gordon, Factors associated with low bone density in patients referred for assessment of bone health. Int. J. Pediatr. Endocrinol. 2013, 4 (2013)
A. Soltani, B. Larijani, P. Khashayar, M. Rezaei Hemami, S. Fakhari, The relationship between anthropometric parameters and bone mineral density in an Iranian referral population. Acta Med. Iran 52, 505–510 (2014)
F. Rossi, S. Perrotta, G. Bellini, L. Luongo, C. Tortora, D. Siniscalco, M. Francese, M. Torella, B. Nobili, V. Di Marzo, S. Maione, Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels. Haematologica 99, 1876–1884 (2014)
P. Wong, P.J. Fuller, M.T. Gillespie, V. Kartsogiannis, P.G. Kerr, J.C. Doery, E. Paul, D.K. Bowden, B.J. Strauss, F. Milat, Thalassemia bone disease: a 19-year longitudinal analysis. J. Bone Miner. Res. 29, 2468–2473 (2014)
G. Mazziotti, A. Bianchi, S. Bonadonna, M. Nuzzo, V. Cimino, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 21, 520–528 (2006)
A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–559 (2008)
J. Zapf, E. Schoenle, E.R. Froesch, Insulin-like growth factors I and II: some biological actions and receptor binding characteristics of two purified constituents of nonsuppressible insulin-like activity of human serum. Eur. J. Biochem. 87, 285–296 (1978)
J.R. Florini, K.A. Magri, D.Z. Ewton, P.L. James, K. Grindstaff, P.S. Rotwein, “Spontaneous” differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II. J. Biol. Chem. 266, 15917–15923 (1991)
C.E. Stewart, P.L. James, M.E. Fant, P. Rotwein, Overexpression of insulin-like growth factor-II induces accelerated myoblast differentiation. J. Cell Physiol. 169, 23–32 (1996)
K.W. Siddals, M. Westwood, J.M. Gibson, A. White, IGF-binding protein-1 inhibits IGF effects on adipocyte function: implications for insulin-like actions at the adipocyte. J. Endocrinol. 174, 289–297 (2002)
M. Ishibe, T. Ishibashi, K. Kaneda, T. Koda, R.N. Rosier, J.E. Puzas, Stimulation of bone formation in vivo by insulin-like growth factor-II in rats. Calcif. Tissue Int. 63, 36–38 (1998)
C.A. Conover, E.W. Johnstone, R.T. Turner, G.L. Evans, F.J. John Ballard, P.M. Doran, S. Khosla, Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis. Growth Horm. IGF Res. 12, 178–183 (2002)
J.G. Kim, C.S. Shin, Y.M. Choi, S.Y. Moon, S.Y. Kim, J.Y. Lee, The relationship among circulating insulin-like growth factor components, biochemical markers of bone turnover and bone mineral density in postmenopausal women under the age of 60. Clin. Endocrinol. (Oxf.) 51, 301–307 (1999)
S. Ormarsdottir, O. Ljunggren, H. Mallmin, H. Olofsson, W.F. Blum, L. Loof, Circulating levels of insulin-like growth factors and their binding proteins in patients with chronic liver disease: lack of correlation with bone mineral density. Liver 21, 123–128 (2001)
S. Amin, B.L. Riggs, E.J. Atkinson, A.L. Oberg, L.J. Melton 3rd, S. Khosla, A potentially deleterious role of IGFBP-2 on bone density in aging men and women. J. Bone Miner. Res. 19, 1075–1083 (2004)
B.L. Riggs, L.J. Melton, R.A. Robb, J.J. Camp, E.J. Atkinson, L. McDaniel, S. Amin, P.A. Rouleau, S. Khosla, A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J. Bone Miner. Res. 23, 205–214 (2008)
S. Boonen, S. Mohan, J. Dequeker, J. Aerssens, D. Vanderschueren, G. Verbeke, P. Broos, R. Bouillon, D.J. Baylink, Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis. J. Bone Miner. Res. 14, 2150–2158 (1999)
P. Gillberg, H. Olofsson, H. Mallmin, W.F. Blum, S. Ljunghall, A.G. Nilsson, Bone mineral density in femoral neck is positively correlated to circulating insulin-like growth factor (IGF)-I and IGF-binding protein (IGFBP)-3 in Swedish men. Calcif. Tissue Int. 70, 22–29 (2002)
R.D. Murray, J.E. Adams, S.M. Shalet, A densitometric and morphometric analysis of the skeleton in adults with varying degrees of growth hormone deficiency. J. Clin. Endocrinol. Metab. 91, 432–438 (2006)
T. Seck, B. Scheppach, S. Scharla, I. Diel, W.F. Blum, H. Bismar, G. Schmid, B. Krempien, R. Ziegler, J. Pfeilschifter, Concentration of insulin-like growth factor (IGF)-I and -II in iliac crest bone matrix from pre- and postmenopausal women: relationship to age, menopause, bone turnover, bone volume, and circulating IGFs. J. Clin. Endocrinol. Metab. 83, 2331–2337 (1998)
Funding
This study was funded in part by the Italian Ministry of Health (Grant Number RF-2009-1519507).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Additional information
This paper is dedicated to the memory of Professor Francesco Minuto.
Rights and permissions
About this article
Cite this article
Scacchi, M., Danesi, L., Cattaneo, A. et al. Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins. Endocrine 53, 551–557 (2016). https://doi.org/10.1007/s12020-016-0865-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-016-0865-1